The management of type 2 diabetes mellitus and CKD can be improved if the beneficial properties of new groups of antidiabetics, such as SGLT2i and GLP1a, on cardiovascular outcomes, including renal function, as well as the use of novel mineralocorticoid receptor antagonists, are considered. This evidence concerns the gene NR3C2 and chronic kidney disease.